BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer’s drug


Biogen’s new Alzheimer’s drug aduhelm saw limited pickup in its first few months on the market.

Storm expected to glaze Pennsylvania, New England in ice

Previous article

Wall Street analysts see a big year ahead for Amazon after fourth-quarter earnings beat

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News